GlassScriptPhysician profile
Dureya Syed
NPI 1699238840
$864.07
in general payments reported to CMS, 2019-2025
15 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $236 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864 · Education: $0.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.68 |
| Education | $0.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $245.42 | 2024-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $105.02 | 2025 | Jynarque |
| Fresenius USA Marketing, INC. | $99.55 | 2025 | Velphoro |
| Travere Therapeutics, INC. | $84.45 | 2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $56.57 | 2025 | |
| Lilly USA, LLC | $50.52 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $28.77 | 2025 | |
| Glaxosmithkline, LLC. | $28.75 | 2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $27.12 | 2025 | Ultomiris |
| Vifor Pharma, INC. | $25.60 | 2024 | Veltassa |
| Ardelyx, INC. | $25.57 | 2024 | Ibsrela |
| Amgen INC. | $24.52 | 2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $23.48 | 2024 | |
| Aurinia Pharma U.S., INC. | $19.98 | 2024 | Lupkynis |
| Kyowa Kirin, INC. | $18.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dureya Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.